Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision BioSciences is viewed favorably because its ARCUS platform is producing differentiated, clinically validated gene-editing programs in two major markets: HBV and DMD. In HBV, PBGENE-HBV delivered the first clinical evidence of direct cccDNA elimination, with 38 doses across 16 patients, 6/6 baseline-pgRNA-positive patients becoming undetectable, and HBsAg declining in 15/15 evaluable patients, supporting a finite viral-cure thesis rather than chronic suppression. In DMD, PBGENE-DMD targets up to ~60% of patients with exon 45–55 mutations and aims to restore ~80% of full-length dystrophin, while imminent first-patient dosing, initial safety by year-end 2026, and efficacy data in early 2027 create multiple catalysts that can de-risk the story.

Precision BioSciences is viewed negatively because the valuation depends on highly uncertain clinical outcomes, with only a 20% probability of success assigned to PBGENE-DMD and 40% to the partnered allogeneic CD19 CAR-T program, while meaningful ARCUS revenues are not modeled until 2030. The framework also assumes a 12% discount rate and a 6.0x terminal EBITDA multiple, underscoring that future value is heavily contingent on execution rather than current fundamentals. In addition, approximately $100M of gross equity raises in 2027E to fund development and potential commercial launch expenses could dilute shareholders, while clinical, commercialization, reimbursement, capital markets, and pricing risks remain substantial.